varicose veins. Varicose veins of lower extremities
Conditions
Interventions
Intervention 1: Intervention group 1: Administration of Heparin ampoule 5000 units in one milliliter subcutaneously, once after surgery, manufactured by Exir Pharmaceutical Company (Iran, Tehran). Int
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients with varicose veins who are candidates for phlebectomy or saphenofemoral junction closure surgery and who complain of varicose veins during the study period will refer to the surgical clinic of Vali-Asr Hospital (PBUH) and Amiral Momineen Hospital (PBUH) in Arak city. Patient consent to participate in the study and cooperate in the research Absence of underlying hemorrhagic disorders Patients' lack of prior anticoagulant treatment No medical history of allergic reactions to heparin or enoxaparin
Exclusion criteria
Exclusion criteria: Patients who are unwilling to continue cooperating or whose information is unavailable will be excluded from the study. Patients with underlying hemorrhagic disorders Patients receiving current anticoagulant therapy. Patients with a medical history of allergic reactions to heparin or enoxaparin. Women of childbearing age who are not actively avoiding pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematoma. Timepoint: one week. Method of measurement: Clinical Examination.;Deep Vein Thrombosis (DVT). Timepoint: Two weeks. Method of measurement: Color Doppler Ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Jafari Nodoushan
Arak University of Medical Sciences
Outcome results
None listed